Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MWN101 Injection in Type 2 Diabetes Mellitus
ChiCTR2500112502Phase 2Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Nov 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MWN101 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Change in HbA1c at week 12. Started Nov 2025; status: completed.
02
Drugs
MWN101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500112502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112502.